NCT06505395View on ClinicalTrials.gov

A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)

PHASE2RecruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

July 30, 2024

Primary Completion Date

August 1, 2027

Study Completion Date

August 1, 2028

Conditions
Gastrointestinal Neuroendocrine Pancreatic Tumor
Interventions
DRUG

SYHX2008 injection

The patients will accept SYHX2008 injection by subcutaneous administration every cycle.

DRUG

Sandostatin LAR@

The patients will accept Sandostatin LAR@ by intra-muscular administration every cycle.

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hosptial, Beijing

All Listed Sponsors
lead

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

INDUSTRY